Evidence From Human Trials on Fungal Beta-Glucans and Health Outcomes

Background

Fungal beta-glucans—specifically β-(1→3,1→6)-D-glucans—are nondigestible polysaccharides derived from yeasts and mushrooms. After resisting digestion in the upper gastrointestinal tract, they reach the colon, where fermentation by gut microbiota may yield immunological and metabolic benefits. Unlike cereal-derived β-glucans (β-(1→3,1→4)), which are better known for cardiometabolic effects, fungal beta-glucans have been less extensively studied. Preclinical work suggests immunomodulatory, anti-tumor, antimicrobial, antioxidative, and radioprotective activities. The review synthesizes RCT evidence on the clinical effects of oral, supplemental fungal beta-glucans across healthy individuals and patients with respiratory illness, allergy, cancer, obesity, or psychological stress.

Objective

To systematically evaluate RCT evidence on the exclusive oral administration of fungal β-(1→3,1→6)-D-glucans and quantify their effects on immune, metabolic, psychological, and disease-specific health outcomes in humans.

Methods

• Databases searched: PubMed, Cochrane Library, Web of Science.
• Search limits: human studies, English language, RCT design, oral β-(1→3,1→6)-D-glucans only (no IV, nasal spray, creams; no cereal-derived β-glucans).
• Screening: From 917 initial records, 34 RCTs met eligibility criteria.
• Population: Healthy volunteers, children, older adults, athletes, patients with respiratory illnesses, allergies, cancer, obesity, osteoarthritis, and HSV-1.
• Interventions: Capsules, syrups, enriched beverages or foods containing β-glucans from Saccharomyces cerevisiae, Pleurotus ostreatus, Lentinula edodes, Ganoderma lucidum, or Aureobasidium pullulans.
• Duration: 4 days to 6.5 months.
• Outcomes: Immunological markers, incidence/severity of URTI, allergy symptoms, psychological metrics, metabolic markers, cancer-related symptoms, and treatment tolerance.

Parameters of Included Interventions

• Dosage range: 2.5 mg/day to 1000 mg/day.
• Frequency: Daily supplementation.
• Form: Capsules most common; some syrups or fortified foods.
• Glucan source distribution:
  • S. cerevisiae: 26 studies
  • A. pullulans, P. ostreatus, L. edodes, G. lucidum: 8 studies

Results

1. Immunomodulation & Respiratory Health

Consistent findings across populations (healthy adults, children, older adults, stressed individuals, athletes):

Clinical-level immune benefits

• Reduced URTI incidence in healthy adults, children, and athletes.
• Reduced symptom severity and duration, including fever, cough, sore throat, nasal symptoms, and sleep disturbance during illness.
• Improved functional wellbeing, including easier breathing during URTI episodes.
• Enhanced physical endurance in children with chronic respiratory issues.

Cellular and molecular outcomes

Results were mixed:

• Some studies showed increases in B-cells, NK cell preservation after exercise, and modulation of cytokines (e.g., increased IFN-γ, IL-12).
• Others showed no significant changes in cytokines, chemokines, or immunoglobulins despite clinical benefits.

2. Allergies

• Adults and children experienced reduction in allergic symptoms (e.g., sneezing, tearing, nasal obstruction).
• Objective markers showed:
  • Lower eosinophilia
  • Stabilization of total IgE in children
  • Decreased Th2 cytokines (IL-4, IL-5) and increased IL-12 in adults with allergic rhinitis.

3. Psychological Wellbeing

Across multiple RCTs in stressed adults:

• Increased vigor, energy, and emotional wellbeing
• Decreased tension, fatigue, depression, anger, confusion
• Improved global mood state

4. Cancer Adjunctive Care

In breast cancer patients:

• Reduced chemotherapy-related symptoms (fatigue, nausea, vomiting, pain, insomnia).
• Modulation of cytokines (↑ IL-12, ↓ IL-4).
• Faster post-mastectomy recovery: lower drain volumes and quicker drain removal.
• Beta-glucans did not improve quality-of-life scales but reduced specific symptom burdens.

5. Obesity and Metabolic Risk

Results varied:

• One study found no metabolic or inflammatory improvement.
• Another found:
  • Reduced waist circumference
  • Lower blood pressure
  • Reductions in IL-6 and TNF-α, and increased IL-10
  • Suggestion of benefit for obesity-related inflammation

6. Other Notable Findings

• HSV-1: Shorter duration of herpes simplex symptoms with P. ostreatus β-glucans.
• Osteoarthritis: Reduced symptom scores and decreased rescue analgesic use.

Safety: No adverse events directly attributed to β-glucans.

Why It Matters

For clinicians, fungal β-(1→3,1→6)-D-glucans represent a well-tolerated adjunctive strategy with the strongest evidence in:

• Reducing URTI incidence and severity, including among high-risk groups such as children, older adults, and athletes.
• Improving allergic disease symptomatology.
• Supporting psychological resilience in stressed populations.
• Adjunctive benefits during cancer treatment.

While mechanistic immune changes are inconsistent at the biomarker level, clinical outcomes repeatedly demonstrate benefit.

Study Limitations

• Heterogeneity across studies in populations, dosing, glucan source, and trial durations precludes meta-analysis.
• Diet not controlled—important given β-glucans rely on gut microbial fermentation.
• Few follow-up assessments after supplementation discontinuation.
• Variability in immunological assays likely contributed to inconsistent molecular findings.

Takeaway for Clinicians

Oral fungal β-(1→3,1→6)-D-glucans are safe, well-tolerated, and demonstrate clinically meaningful benefits in respiratory illness prevention, allergy management, psychological wellbeing, and supportive cancer care. While optimal dosing and mechanistic pathways remain to be clarified, the overall evidence supports their use as a nonpharmacologic immunomodulatory supplement.